



ASX release

5 November 2008

AtCor Medical anticipates continued strong growth in FY2009

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, yesterday announced that the company anticipated a 45 per cent increase in sales for FY2009 over FY2008.

At yesterday's annual general meeting, Duncan Ross, CEO of AtCor Medical, said: "Sales momentum is continuing, and AtCor Medical is on track for another strong year as we drive the business towards sustainability. We have already secured new US pharmaceutical trial contracts valued at \$US3 million during FY2009 and expect more through the year. Sales of SphygmoCor[®] systems to the specialist clinical sector are ramping up, and we will introduce our new, portable SphygmoCor[®] system this week to further support our growth."

Mr. Ross said the company was well funded with cash of \$3.3 million at 30 September 2008, unchanged from 30 June 2008. Increasing sales, healthy margins and a stable expense base are all contributing to a reduction in operating cash usage.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,700 SphygmoCor[®] systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au